Abstract
Chemokine receptors have been recognised as attractive targets for drug development. Although the notion that chemokine receptor antagonism can significantly reduce inflammation has been supported by evidence obtained with modified chemokines and antibodies to chemokines or their receptors, the focus of most pharmaceutical organisations have been small molecular weight antagonists. A small molecule antagonist with high affinities to both human and mouse CCR1 receptors has been prepared by modifications of a lead compound, xanthene-9-carboxamide. This molecule also functions as a human CCR3 antagonist. This molecule should be an important tool in establishing the role of CCR1 and CCR3 receptors in established murine models of disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
